Charles River Laboratories points to potential to accelerate rate of mergers and acquisitions to hit goal of doubling revenues every five years.
Since 2013, Charles River has invested upward of $2bn (€1.8bn) in 13 acquisitions, transforming its business to the point that recent takeovers now account for around one-third of revenues.
The takeovers helped Charles River double its revenue over the past five years. With Charles River aiming to double sales again over the next five years, attention has turned to the deals the early-stage contract research organization (CRO) will strike to hit its target.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Outsourcing-Pharma